FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960863555> ?p ?o ?g. }

• W2960863555 endingPage "189" @default.
• W2960863555 startingPage "179" @default.
• W2960863555 abstract "Patients with liver disease have increased risk of thrombosis and bleeding but are typically excluded from trials of direct oral anticoagulant agents. This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), clinical efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation (AF) and history of liver disease. ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial Infarction Study 48) was a randomized, double-blind trial comparing edoxaban with warfarin in patients with AF followed for 2.8 years. History of liver disease was defined as investigator-reported liver disease or >2-fold transaminase elevation at randomization. The primary efficacy and safety endpoints of stroke or systemic embolic event (SSEE) and major bleeding were assessed stratified by history of liver disease. PK/PD assessments of edoxaban included endogenous and extrinsic factor Xa activity and edoxaban concentration. Among 21,105 patients, 1,083 (5.1%) had a history of liver disease; they had a higher prevalence of many comorbidities. The adjusted risks of SSEE were similar (adjusted hazard ratio [HRadj]: 0.90; 95% confidence interval [CI]: 0.67 to 1.22; p = 0.50), but major bleeding was more common in patients with liver disease (HRadj: 1.38; 95% CI: 1.10 to 1.74; p = 0.005). There were no significant differences in PK/PD assessment of edoxaban in patients with versus without liver disease. The HRs for higher-dose edoxaban versus warfarin for SSEE were 0.86 (95% CI: 0.73 to 1.01) in patients without and 1.11 (95% CI: 0.54 to 2.30) with liver disease (p for interaction [pint] = 0.47), major bleeding 0.80 (95% CI: 0.70 to 0.91) in patients without and 0.91 (95% CI: 0.56 to 1.47) with liver disease (pint = 0.63). There were no significant differences in hepatic adverse events between the 2 treatment groups. Among patients with AF receiving oral anticoagulation, bleeding, but not thromboembolic events, was increased in patients with liver disease. A history of liver disease did not alter the relative efficacy and safety of edoxaban compared with warfarin. Hepatic adverse events were similar between edoxaban and warfarin." @default.
• W2960863555 created "2019-07-23" @default.
• W2960863555 creator A5013162997 @default.
• W2960863555 creator A5016322021 @default.
• W2960863555 creator A5019612250 @default.
• W2960863555 creator A5022267024 @default.
• W2960863555 creator A5024483711 @default.
• W2960863555 creator A5028971151 @default.
• W2960863555 creator A5034353627 @default.
• W2960863555 creator A5042871525 @default.
• W2960863555 creator A5072828160 @default.
• W2960863555 creator A5078033695 @default.
• W2960863555 creator A5078643079 @default.
• W2960863555 creator A5085897222 @default.
• W2960863555 creator A5087033748 @default.
• W2960863555 date "2019-07-01" @default.
• W2960863555 modified "2023-10-02" @default.
• W2960863555 title "Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease" @default.
• W2960863555 cites W1480212256 @default.
• W2960863555 cites W1586488555 @default.
• W2960863555 cites W1897345853 @default.
• W2960863555 cites W1964424199 @default.
• W2960863555 cites W1965320794 @default.
• W2960863555 cites W1981297163 @default.
• W2960863555 cites W2064012881 @default.
• W2960863555 cites W2096246254 @default.
• W2960863555 cites W2097854437 @default.
• W2960863555 cites W2120397203 @default.
• W2960863555 cites W2123326326 @default.
• W2960863555 cites W2124273275 @default.
• W2960863555 cites W2136489990 @default.
• W2960863555 cites W2138407822 @default.
• W2960863555 cites W2144820006 @default.
• W2960863555 cites W2153804622 @default.
• W2960863555 cites W2162508946 @default.
• W2960863555 cites W2170740817 @default.
• W2960863555 cites W2211816300 @default.
• W2960863555 cites W2263934434 @default.
• W2960863555 cites W2529298923 @default.
• W2960863555 cites W2533474819 @default.
• W2960863555 cites W2558447421 @default.
• W2960863555 cites W2565690243 @default.
• W2960863555 cites W2567030468 @default.
• W2960863555 cites W2568547457 @default.
• W2960863555 cites W2603502286 @default.
• W2960863555 cites W2751199194 @default.
• W2960863555 cites W2770913430 @default.
• W2960863555 cites W2792634476 @default.
• W2960863555 cites W2802816738 @default.
• W2960863555 cites W2809811770 @default.
• W2960863555 cites W2888980860 @default.
• W2960863555 doi "https://doi.org/10.1016/j.jacc.2019.04.061" @default.
• W2960863555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31296289" @default.
• W2960863555 hasPublicationYear "2019" @default.
• W2960863555 type Work @default.
• W2960863555 sameAs 2960863555 @default.
• W2960863555 citedByCount "33" @default.
• W2960863555 countsByYear W29608635552019 @default.
• W2960863555 countsByYear W29608635552020 @default.
• W2960863555 countsByYear W29608635552021 @default.
• W2960863555 countsByYear W29608635552022 @default.
• W2960863555 countsByYear W29608635552023 @default.
• W2960863555 crossrefType "journal-article" @default.
• W2960863555 hasAuthorship W2960863555A5013162997 @default.
• W2960863555 hasAuthorship W2960863555A5016322021 @default.
• W2960863555 hasAuthorship W2960863555A5019612250 @default.
• W2960863555 hasAuthorship W2960863555A5022267024 @default.
• W2960863555 hasAuthorship W2960863555A5024483711 @default.
• W2960863555 hasAuthorship W2960863555A5028971151 @default.
• W2960863555 hasAuthorship W2960863555A5034353627 @default.
• W2960863555 hasAuthorship W2960863555A5042871525 @default.
• W2960863555 hasAuthorship W2960863555A5072828160 @default.
• W2960863555 hasAuthorship W2960863555A5078033695 @default.
• W2960863555 hasAuthorship W2960863555A5078643079 @default.
• W2960863555 hasAuthorship W2960863555A5085897222 @default.
• W2960863555 hasAuthorship W2960863555A5087033748 @default.
• W2960863555 hasConcept C126322002 @default.
• W2960863555 hasConcept C127413603 @default.
• W2960863555 hasConcept C164705383 @default.
• W2960863555 hasConcept C207103383 @default.
• W2960863555 hasConcept C2776301958 @default.
• W2960863555 hasConcept C2777075537 @default.
• W2960863555 hasConcept C2778810321 @default.
• W2960863555 hasConcept C2779161974 @default.
• W2960863555 hasConcept C2780290652 @default.
• W2960863555 hasConcept C2780645631 @default.
• W2960863555 hasConcept C44249647 @default.
• W2960863555 hasConcept C71924100 @default.
• W2960863555 hasConcept C78519656 @default.
• W2960863555 hasConcept C90924648 @default.
• W2960863555 hasConceptScore W2960863555C126322002 @default.
• W2960863555 hasConceptScore W2960863555C127413603 @default.
• W2960863555 hasConceptScore W2960863555C164705383 @default.
• W2960863555 hasConceptScore W2960863555C207103383 @default.
• W2960863555 hasConceptScore W2960863555C2776301958 @default.
• W2960863555 hasConceptScore W2960863555C2777075537 @default.
• W2960863555 hasConceptScore W2960863555C2778810321 @default.
• W2960863555 hasConceptScore W2960863555C2779161974 @default.

• next